GlassScriptPhysician profile
Ricardo Leyva
NPI 1427436849
$10,383.31
in general payments reported to CMS, 2019-2025
38 companies · $2,297 in 2025
The $2,297 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,356 · 2022: $1,890 · 2023: $1,918 · 2024: $1,922 · 2025: $2,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,121 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,121.14 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,054.55 | 2021-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $966.94 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $931.99 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $699.83 | 2021-2025 | Trintellix |
| Glaxosmithkline, LLC. | $609.97 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $595.16 | 2021-2025 | |
| Pfizer INC. | $569.63 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $514.65 | 2021-2024 | Xarelto, Spravato |
| Astrazeneca Pharmaceuticals LP | $502.77 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $449.91 | 2021-2025 | Xifaxan |
| Novo Nordisk INC | $411.20 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.92 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $367.00 | 2021-2025 | Verquvo, Steglatro, Capvaxive |
| Ardelyx, INC. | $317.40 | 2023-2025 | Ibsrela |
| Radius Health, INC. | $307.63 | 2021-2025 | Tymlos |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $197.66 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $176.00 | 2021-2024 | Eliquis |
| Sanofi-Aventis U.S. LLC | $154.39 | 2021-2023 | |
| Astellas Pharma US INC | $149.60 | 2021 | |
| Nestle Healthcare Nutrition INC. | $148.10 | 2021-2023 | |
| Exact Sciences Corporation | $124.19 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbott Laboratories | $120.66 | 2021-2023 | Freestyle Libre 3 |
| Aimmune Therapeutics, INC. | $98.64 | 2024-2025 | Zenpep |
| Sumitomo Pharma America, INC. | $97.97 | 2023-2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $85.43 | 2021-2023 | Livalo |
| Novartis Pharmaceuticals Corporation | $57.88 | 2022-2023 | |
| Eisai INC. | $57.17 | 2021-2025 | |
| Biogen, INC. | $53.14 | 2021 | |
| Idorsia Pharmaceuticals US INC | $47.13 | 2023-2024 | Quviviq |
| Scilex Pharmaceuticals INC. | $18.47 | 2021 | |
| Shield Therapeutics INC | $18.05 | 2023 | Accrufer |
| Dexcom, INC. | $17.99 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $17.94 | 2023 | Rexulti |
| Esperion Therapeutics, INC. | $15.62 | 2021 | |
| Axsome Therapeutics, INC. | $15.04 | 2022 | |
| Ani Pharmaceuticals, INC. | $14.83 | 2024 | Purified Cortrophin Gel |
| Genentech USA, INC. | $14.59 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Leyva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.